Free Trial

Artiva Biotherapeutics (ARTV) News Today

Artiva Biotherapeutics logo
$10.96 -0.34 (-3.01%)
(As of 11/20/2024 ET)
Cantor Fitzgerald Estimates ARTV FY2024 Earnings
Artiva Biotherapeutics, Inc. stock logo
Cantor Fitzgerald Forecasts ARTV FY2024 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects tha
Artiva Biotherapeutics, Inc. stock logo
Wedbush Has Bearish Forecast for ARTV FY2024 Earnings
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush cut their FY2024 earnings per share estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Announces Earnings Results
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24).
Artiva Biotherapeutics, Inc. stock logo
Needham & Company LLC Reiterates "Buy" Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday.
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD Cowen
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Shares Down 5.4% - Time to Sell?
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4% - Time to Sell?
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by Wedbush
Wedbush reaffirmed an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday.
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Wedbush
Artiva Biotherapeutics, Inc. stock logo
Artiva Biotherapeutics, Inc.'s (NASDAQ:ARTV) Quiet Period Will End on August 28th
Artiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) quiet period is set to expire on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During Artiva Biotherapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Artiva Biotherapeutics shares get Overweight rating
Artiva Biotherapeutics, Inc. stock logo
Analysts Set Expectations for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV)
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at Wedbush issued their Q2 2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten expects that the company will earn ($1.5
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. stock logo
Jefferies Financial Group Begins Coverage on Artiva Biotherapeutics (NASDAQ:ARTV)
Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday. They set a "buy" rating and a $21.00 price target for the company.
Artiva Biotherapeutics Inc ARTV
Artiva Biotherapeutics Inc (ARTV)
Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

ARTV Media Mentions By Week

ARTV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARTV
News Sentiment

0.42

0.45

Average
Medical
News Sentiment

ARTV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARTV Articles
This Week

11

2

ARTV Articles
Average Week

Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ARTV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners